Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings.

ABSTRACT:

Introduction

Androgen-receptor pathway inhibitors such as abiraterone and enzalutamide have demonstrated clinical benefit in patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to conduct a meta-analysis of published real-world evidence studies comparing outcomes among patients treated with enzalutamide or abiraterone in the first-line setting.

Methods

We conducted a systematic literature review to identify eligible studies. Evaluated outcomes were: overall survival (OS), progression-free survival, prostate-specific antigen (PSA) progression-free survival, PSA response, all-grade adverse events, grade ≥3 adverse events, treatment discontinuation, and dose reduction. Each outcome's suitability for meta-analysis was evaluated by ass

SUBMITTER: Aprikian A 

PROVIDER: S-EPMC11849621 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature